The equine herpesvirus-1 IR3 gene that lies antisense to the sole immediate-early (IE) gene is trans-activated by the IE protein, and is poorly expressed to a protein  by Ahn, Byung Chul et al.
07) 15–25
www.elsevier.com/locate/yviroVirology 363 (20The equine herpesvirus-1 IR3 gene that lies antisense to the sole
immediate-early (IE) gene is trans-activated by the IE protein,
and is poorly expressed to a protein
Byung Chul Ahn, Jonathan E. Breitenbach, Seong K. Kim, Dennis J. O'Callaghan ⁎
Center for Molecular and Tumor Virology, Department of Microbiology and Immunology, Louisiana State University Health Sciences Center,
1501 Kings Highway, PO Box 33932, Shreveport, LA 71130-3932, USA
Received 18 July 2006; returned to author for revision 17 November 2006; accepted 18 January 2007
Available online 15 February 2007Abstract
The unique IR3 gene of equine herpesvirus 1 (EHV-1) is expressed as a late 1.0-kb transcript. Previous studies confirmed the IR3 transcription
initiation site and tentatively identified other cis-acting elements specific to IR3 such as a TATA box, a 443 base pair 5′untranslated region (UTR),
a 285 base pair open reading frame (ORF), and a poly adenylation (A) signal [Holden, V.R., Harty, R.N., Yalamanchili, R.R., O'Callaghan, D.J.,
1992. The IR3 gene of equine herpesvirus type 1: a unique gene regulated by sequences within the intron of the immediate-early gene. DNA Seq.
3, 143–152]. Transient transfection assays revealed that the IR3 promoter is strongly trans-activated by the IE protein (IEP) and that coexpression
of the IEP with the early EICP0 and IR4 regulatory proteins results in maximal trans-activation of the IR3 promoter. Gel shift assays revealed that
the IEP directly binds to the IR3 promoter region. Western blot analysis showed that the IR3 protein produced in E. coli was detected by
antibodies to IR3 synthetic peptides; however, the IR3 protein was not detected in EHV-1 infected cell extracts by these same anti-IR3 antibodies,
even though the IR3 transcript was detected by northern blot. These findings suggest that the IR3 may not be expressed to a protein. Expression of
an IR3/GFP fusion gene was not observed, but expression of a GFP/IR3 fusion gene was detected by fluorescent microscopy. In further attempts to
detect the IR3/GFP fusion protein using anti-GFP antibody, western blot analysis showed that the IR3/GFP fusion protein was not detected in
vivo. Interestingly, a truncated form of the GFP/IR3 protein was synthesized from the GFP/IR3 fusion gene. However, GFP/IR3 and IR3/GFP
fusion proteins of the predicted sizes were synthesized by in vitro coupled transcription and translation of the fusion genes, suggesting poor
expression of the IR3 protein in vivo. The possible role of the IR3 transcript in EHV-1 infection is discussed.
© 2007 Elsevier Inc. All rights reserved.Keywords: Equine herpesvirus 1; Herpesvirus alpha gene regulation; Unique IR3 gene of EHV-1; Herpesviral regulatory IR3 RNAIntroduction
Equine herpesvirus-1 (EHV-1) belongs to the Alphaherpes-
virinae subfamily, and its genome of 155,000 bp (Telford et al.,
1992) is comprised of a unique long region covalently linked to
a short region that has a unique segment bracketed by a pair of
identical internal and terminal repeat (IR and TR) sequences
(Henry et al., 1981; Whalley et al., 1981; Ruyechan et al.,
1982). EHV-1 has been studied as a model of gene regulation of
alphaherpesviruses during lytic and persistent infection (O'Cal-
laghan and Osterrieder, 2007; Ebner and O'Callaghan, 2006).⁎ Corresponding author. Fax: +1 318 675 5764.
E-mail address: docall@lsuhsc.edu (D.J. O'Callaghan).
0042-6822/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2007.01.024As is the case with other herpesviruses, EHV-1 genes are
regulated in an immediate-early, early, and late fashion by viral
regulatory proteins (Caughman et al., 1985; Gray et al., 1987a,
1987b). Six EHV-1 regulatory proteins have been described: the
sole immediate-early protein (IEP; Caughman et al., 1988;
Grundy et al., 1989; Harty et al., 1990), early proteins EICP0P
(Everett et al., 1993, 1995; Bowles et al., 1997, 2000; Yao et al.,
2003), IR4 (EICP22) (Holden et al., 1994, 1995), UL5
(EICP27) (Zhao et al., 1992, 1995; Smith et al., 1993), and
IR2 (Harty and O'Callaghan, 1991; Caughman et al., 1995; Kim
et al., 2006), and late tegument protein ETIF (Elliott, 1994;
Elliott and O'Hare, 1995; Lewis et al., 1997; Kim and
O'Callaghan, 2001). During productive viral replication, the
IE gene is first trans-activated by the multi-functional ETIF
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2006), and the essential IEP trans-activates early and some late
genes (Smith et al., 1992, 1994; Kim et al., 1997; Garko-
Buczynski et al., 1998). Two different functions of the IEP have
been described: trans-activation of early and late genes, and
down-regulation of its own expression (Kim et al., 1995). Also,
the IEP interacts with cellular factors (Kim et al., 2001, 2003;
Jang et al., 2001; Albrecht et al., 2003) and with other viral
regulatory proteins that have both synergistic (Smith et al.,
1993; Kim et al., 1997; Derbigny et al., 2000, 2002; Albrecht et
al., 2004, 2005) and antagonistic (Kim et al., 2004) effects on
EHV-1 gene expression. The IR2, a truncated form of the IEP
that lacks aa 1–322 including the trans-activation domain
(Harty and O'Callaghan, 1991; Caughman et al., 1995), down-
regulates EHV-1 genes (Kim et al., 2006).
In addition to the six documented EHV-1 regulatory genes, a
seventh potential regulatory IR3 gene unique to EHV-1 was
predicted (Holden et al., 1992). S1 nuclease, northern blot, and
primer extension analyses revealed the 1.0-kb IR3 transcript to
map antisense to the 5′ end of the IE transcript, such that 117 nt
of the IR3 transcript overlap the 5′ end of the IE mRNA
(Holden et al., 1992). Also, these data tentatively identified theFig. 1. The IR3 gene of EHV-1. (A) Diagram of the IR3 promoter region and IR3
transcription initiation site (Tci). The 117 nt of the IE/IR3 transcript overlapping sequ
IE splicing donor site. Five IR3 promoter regions were PCR-amplified and cloned in
IR3(−280/+443)-Luc, IR3(−946/+443)-Luc and IR3(-946/+38)-Luc include the IR3
include the IR3 TATA box sequences. (B) The IR3 promoter activity. Promoter assay
described in Materials and methods. RK13 cells were transfected with 1.0 pmol o
+443)-Luc, pIR3(−946/−85)-Luc, or pIR3(−946/+38)-Luc] without effector plasmi
RLU indicates relative luciferase units. Each experiment was carried out in triplicate
deviations.IR3 cis-acting elements such as a TATA box, a 5′untranslated
region (UTR), an open reading frame (ORF), and a poly(A)
signal. To further characterize the IR3 gene, we present results
demonstrating that the promoter of the IR3 gene is trans-
activated by the direct binding of the IEP alone to the IR3
promoter, and also by the IEP in concert with the early EICP0P
or IR4 regulatory proteins. In addition, translation of IR3 is very
poor in vivo even though the IR3 transcript was readily detected
in EHV-1 infected cells.
Results
IR3 promoter activation
Previous studies (Holden et al., 1992) established the
presence of the late 1.0-kb IR3 transcript, mapped the IR3
transcription initiation (Tci) site, and predicted potential cis-
acting elements such as a TATA box, a 5′UTR of 443 bases, an
ORF of 285 bases, and a poly(A) signal (Fig. 1A, top). To further
characterize the IR3 promoter, four constructs harboring
potential IR3 promoters upstream of the luciferase reporter
gene, [IR3(+43/+443)-Luc, IR3(−280/+443)-Luc, IR3(−946/promoter location. The (±) numbers indicate nucleotide distances from the IR3
ences is located between +227 and +343. IESA, IE splicing acceptor site; IESD,
to the pGL3-Basic luciferase vector as described in Materials and methods. The
TATA box sequences, and IR3(+43/+443)-Luc and IR3(−946/−85)-Luc do not
s of IR3 promoter sequences linked to the luciferase reporter were carried out as
f reporter plasmid [pIR3(+43/+443)-Luc, pIR3(−280/+443)-Luc, pIR3(−946/
d, and luciferase activity was measured as described in Materials and methods.
. Data are averages of independent experiments, and error bars indicate standard
Fig. 2. Trans-activation assays of the IR3(−946/+443)-Luc reporter construct
by EHV-1 regulatory proteins. (A) 1.0 pmol of pIR3(−946/+443)-Luc reporter
plasmid and 0.5 pmol of the single effector plasmid [pSVIE, pSV-IR3 ORF,
pSVEICP0, pSVEICP22 (IR4), pSVEICP27 (UL5), or pSVETIF] were
cotransfected into RK13 cells, and promoter activities were determined as
described in Materials and methods. (B) 1.0 pmol of pIR3(−946/+443)-Luc
reporter plasmid and 0.5 pmol each of two effector plasmids [pSVIE, pSV-IR3,
pSVEICP0, pSVEICP22 (IR4), or pSVEICP27 (UL5)] were cotransfected into
RK13 cells, and luciferase activity was measured as described in Materials and
methods. RLU indicates relative luciferase units. Each experiment was carried
out in triplicate. Data are averages of three independent experiments, and error
bars indicate standard deviations.
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bottom) and assayed for promoter activity in the absence of an
effector plasmid by the luciferase assay. Promoter analyses
indicated that the IR3(−946/+443)-Luc (Fig. 1B, bar 3) showed
the greatest level of luciferase activity among the four constructs
(Fig. 1B, bars 1–4). The IR3(−280/+443)-Luc construct (Fig.
1B, bar 2) showed a lesser level of luciferase activity but values
above that of the control plasmid, whereas the IR3(−946/−85)-
Luc construct (Fig. 1B, bar 4) that lacks the IR3 TATA box
sequence exhibited only background levels of activity. Surpris-
ingly, the IR3(+43/+443)-Luc construct (Fig. 1B, bar 1)
exhibited promoter activity even though it does not contain the
IR3 TATA box and Tci site. Based on these observations, we
generated and assayed an IR3(−946/+38)-Luc construct that
lacks IR3(+43/+443) sequences and found that this construct
exhibited maximal activity (Fig. 1B, bar 5) compared to that of
the IR3(−946/+443)-Luc vector (Fig. 1B, bar 3). Although we
cannot exclude the possibility that the longer 5′UTR may
retard downstream gene expression, these results suggest that
the IR3(+43/+443) sequences may harbor a negative regula-
tory element. Overall, these analyses indicate that transcription
of the IR3 is maximally directed by the IR3(−946/+38)
region proximal to the IR3 gene and that the 5′UTR of the
IR3(+43/+443) may be involved in interference of IR3 gene
expression.
The IEP trans-activates the IR3 promoter, and EICP0P and
IR4 synergistically enhance the IEP-mediated trans-activation
Although the IR3(−946/+38)-Luc showed the strongest
promoter activity among the IR3 constructs tested, the IR3
(−946/+443)-Luc promoter was used in further trans-activation
studies with EHV-1 regulatory proteins as the reporter vector
because this reporter plasmid harbors the authentic IR3
sequence in the EHV-1 genome. Cotransfection assays of
pIR3(−946/+443)-Luc reporter plasmid and effector plasmids
expressing EHV-1 regulatory proteins IEP, EICP0P, IR4, UL5,
ETIF, or IR3 showed that the IR3 is trans-activated only by the
IEP (Fig. 2A, bar 1). Interestingly, the EICP0P that is a potent
trans-activator of most EHV-1 genes failed to trans-activate
the IR3 promoter (Fig. 2A, bar 3). Also, other EHV-1 regulatory
proteins were unable to trans-activate the IR3 promoter (Fig.
2A, bars 2, 4, 5, and 6).
In addition to its ability to activate (Holden et al., 1995; Smith
et al., 1993; Kim et al., 1997; Bowles et al., 2000) or repress
(Kim et al., 2003, 2004) expression of some EHV-1 promoters,
the IEP can interact with EHV-1 early regulatory proteins to
govern viral gene expression. Whether the IEP functions
synergistically with other regulatory proteins to affect IR3
gene expression was examined by cotransfection of reporter
plasmid pIR3(−946/+443)-Luc and effector plasmids expres-
sing other EHV-1 regulatory proteins. The findings revealed that
the IEP acts synergistically on the IR3 promoter with the early
EICP0P (Fig. 2B, bar 3) and IR4 (Fig. 2B, bar 4), both of which
bind to the IEP (Derbigny et al., 2000; Kim et al., 1995, 1997,
2003). The IR4 has been shown to greatly enhance the DNA-
binding and trans-activation abilities of the IEP (Kim et al.,1995, 1997). The finding that the EICP0P enhanced the level of
expression of the reporter construct achieved by the IEP was
unexpected since this early regulatory protein has been shown to
strongly antagonize IEP-mediated trans-activation of previously
tested EHV-1 promoters (Bowles et al., 2000; Kim et al., 2003).
The IEP binds to the IR3 promoter sequences
The IEP is a major trans-activator of the IR3 promoter and
requires specific DNA sequences to bind for promoter trans-
activation (Kim et al., 1995). Sequence analysis within the IR3
(−946/+443) showed that the IR3 harbors IEP binding sites.
The DNA sequence corresponding to IR3 5′UTR(+1/+443)
harbors three IEP binding sites: (+119)atcgt(+123), (+281)
atcga(+285), and (+338)atctt(+342). The DNA sequence
corresponding to IR3(−946/+38) region harbors four IEP bin-
ding sites: (−902)ctcgc(−898), (−740)atcgc(−736), (−631)
atcgc(−627), and (−353)ctcgc(−349). In addition to sequence
analysis, direct binding of IEP to the IR3 promoter was
demonstrated by gel shift assays using IR3 promoter sequences,
GST-IEP, and anti-IEP monoclonal antibody A1.4. The IEP
bound to the IR3 promoter sequences (Fig. 3, lanes 2 and 8), but
GST showed no binding to the IR3 promoter sequences (Fig. 3,
lanes 1 and 7). The addition of excessive non-radiolabeled IR3
promoter sequences as a specific competitor resulted in the
Fig. 3. The IE protein interacts with the IR3 promoter. Binding assays of the DNA sequences of the IR3 promoter region and the GST-IE protein (GST-IEP) were
performed as described in Materials and methods. Lanes 1 to 6 are the IR3 (+43/+443) DNA-IEP binding assays. Lanes 7 to 12 are IR3(−946/+38) DNA-IEP binding
assays. Lanes 1 and 7 show that GST protein failed to bind to the IR3 promoter regions. Lanes 2 and 8 show DNA-GST-IEP binding. Lanes 3 and 9 show DNA-GST-
IEP binding in the presence of the nonspecific competitor, SP6T7 promoter sequences. Lanes 4 and 10 show that DNA-GST-IEP binding is blocked by the specific
competitor, IR3 promoter DNA sequences. Lanes 5 and 11 show DNA-GST-IEP binding in the presence of control antiserum, α-GFP monoclonal antibody. Lanes 6
and 12 show that DNA-GST-IEP binding complexes were supershifted by specific α-IEP antibody.
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(Fig. 3, lanes 4 and 10), whereas the addition of SP6T7 DNA
sequences as a nonspecific competitor failed to inhibit IEP
binding to radio-labeled IR3 sequences (Fig. 3, lanes 3 and 9).
To confirm that the observed DNA/protein complex contained
the IEP, an anti-IEP monoclonal antibody was added to the IR3
promoter DNA/IEP complex reaction, and this resulted in a
supershift of the IR3 promoter DNA/IEP complex (Fig. 3, lanes
6 and 12), whereas addition of a control nonspecific antibody
(anti-GFP antibody) failed to supershift the IR3 promoter DNA/
IEP complex (Fig. 3, lanes 5 and 11).
The IR3 gene is minimally translated
Next, studies to analyze expression of the IR3 ORF to a
protein were performed. Northern blot analysis showed that the
approximate 1.0-kb and 0.6-kb IR3 transcripts were synthesized
in EHV-1 infected RK13 cells (Fig. 4A). Promoter activity of
IR3 5′UTR(+1/+443) may explain why the 0.6-kb IR3 transcript
was detected. Once the IR3 transcript was detected, the
experiments to detect an IR3 protein in EHV-1 infected cells
were carried out. Repeated efforts to detect an IR3 protein in
EHV-1 infected cells using two independently generated anti-
IR3 antisera to predicted epitope-bearing peptides within the IR3
ORF were unsuccessful (Fig. 4B), even though the early EHV-1
UL5 protein was readily detected in these same infected cell
extracts by an anti-UL5 antiserum (Fig. 4C). However, in
immunoprecipitation assays, these same anti-IR3 antisera were
able to detect the IR3 protein generated in IVTT (in vitro coupled
transcription and translation) reactions (Fig. 4D, lane 4), andfailed to immunoprecipitate IVTT-generated GFP as a negative
control (Fig. 4D, lane 5). As shown in lanes 2 and 3 of Fig. 4D,
both the IR3 protein and GFP, respectively, were synthesized in
IVTT reactions. To examine the ability of IR3 antibodies to
detect the IR3 protein under different conditions, western blot
analyses were performed using anti-IR3 antibodies and a
glutathione S-transferase (GST)/IR3 fusion protein generated
in E. coli. Western blot analysis showed that the approximately
38 kDa GST/IR3 fusion protein was detected by anti-IR3
antibody (Fig. 5A, lane 4), and UL5 was detected by anti-UL5
antibody as a positive control (Fig. 5A, lane 3). However, the
approximately 10 kDa IR3 protein was not detected in EHV-1
infected cell extracts (Fig. 5A, lane 3) or mock infected cell
extracts as a negative control (Fig. 5A, lane 2).
To determine whether anti-IR3 antibody is able to pull down
metabolically radiolabeled IR3 protein, immunoprecipitation
assays were performed using extracts of EHV-1 infected cells
incubated with S35 labeled amino acids, anti-IR3 antibody, anti-
UL5 antibody as a positive control, or preimmune serum.
Immunoprecipitation assays showed that anti-IR3 antibody
precipitated IR3 protein from the IVTT reactions (Fig. 5B, lane
3), but not from extracts of radiolabeled mock infected cells
(Fig. 5B, lane 4) or EHV-1 infected cells (Fig. 5B, lane 6). As
expected, the pre-immune serum failed to precipitate the IR3
protein from either IR3 IVTT reactions (Fig. 5B, lane 2) or
extracts of EHV-1 infected cells (Fig. 5B, lane 5). However,
anti-UL5 antibody precipitated the EHV-1 UL5 protein from
infected cell extracts (Fig. 5B, lane 9) and the UL5 IVTT
reactions (Fig. 5B, lane 10). As negative controls, anti-UL5
antibody failed to precipitate the UL5 protein from mock
Fig. 4. Detection of the IR3 transcript and IR3 protein. Northern blot of IR3
RNA, radiolabeling of IR3 and GFP proteins, immunoprecipitation, and western
blot procedures were performed as described in Materials and methods. (A)
Northern blot of the IR3 transcript. EHV-1 infected RK13 cells were harvested
at 1, 3, 5, and 7 h.p.i. Total RNAs were extracted using RNA-Bee (Tel-Test, Inc.,
Friendwood, TX) and separated in 3% PAGE-8 M urea gels, and the IR3
transcript was detected by using a radio-labeled IR3 ORF DNA probe. M, RNA
Century Marker Plus (Ambion, Austin, TX). (B) Detection of the IR3 protein.
Detection of the IR3 protein in EHV-1 infected cells was performed by western
blot using anti-IR3 peptide antiserum to the 20-mer peptide (see Materials and
methods). (C) Detection of UL5. UL5 in EHV-1 KyA infected cells was detected
by western blot using anti-UL5 antiserum. (D) Detection of the IR3 protein by
IVTT and immunoprecipitation. Samples of the IVTT reactions (Input, lanes 2
and 3) and IVTT proteins immunoprecipitated by anti-IR3 antiserum (I/P, lanes
4 and 5) were separated by SDS-PAGE. Lane 4 shows that the IR3 protein
generated by IVTT was immunoprecipitated by anti-IR3 antiserum. Lane 5
shows that the anti-IR3 antiserum failed to precipitate GFP generated by IVTT.
The “Marker” lane shows the sizes of 14C-labeled protein molecular markers
(CFA 645, Amersham Biosciences, Piscataway, NJ).
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serum did not detect UL5 protein in EHV-1 infected cell extracts
(Fig. 5B, lane 8). These results from experiments that employed
radiolabeled proteins of infected cells further suggest that the
IR3 protein may not be produced in EHV-1 infected cells.
We could not exclude the possibility, however, that the anti-
IR3 antibodies might not detect an IR3 protein produced in vivo
if the IR3 protein was synthesized in very small amounts
beyond the level of detection by these antibodies. To normalize
expression of the IR3 protein to a known control, we transfected
RK-13 cells with plasmid pSV-IR3 expressing the IR3 ORF, orplasmid pSVIE expressing the IE ORF, or cotransfected cells
with both of these expression plasmids. The presence of the IE
and IR3 proteins in the plasmid transfected cells and in EHV-1
infected cells was examined by western blot analysis using anti-
IEP or anti-IR3 antiserum. The ∼200 kDa IEP was readily
detected in extracts of EHV-1 infected, pSVIE transfected, and
pSVIE/pSV-IR3 cotransfected cells (Fig. 6A, lanes 3, 4, and 5,
respectively) by an anti-IEP antiserum, but the ∼10 kDa IR3
protein (area in box) was not detected in extracts of EHV-1
infected or in plasmid transfected cells by anti-IR3 antiserum
(Fig. 6B, lanes 3, 4, and 5). In further attempts to determine
whether the IR3 gene produces a protein in vivo, we constructed
fusion genes IR3 ORF/GFP such that the IR3 ORF is fused to
the 5′ end of the GFP gene, and GFP/IR3 ORF such that the
IR3 ORF is fused to the 3′ end of the GFP gene under the
control of the CMV-IE promoter, and transfected these plasmids
into equine NBL-6 cells.
Strong GFP expression was observed in cells transfected with
the positive control pSP6T7-EGFP-N1 (Fig. 7A) and in cells
transfected with pCMV-GFP/IR3 ORF (Fig. 7B). GFP expres-
sion was barely detected in cells transfected with the plasmid that
would express the IR3 ORF/GFP fusion gene (Fig. 7C). The
expression of these fusion genes was also examined by western
blot analysis using cell extracts of the plasmid transfected cells
and an anti-GFP antiserum. GFP of the correct molecular size
(27 kDa) was detected in extracts of cells transfected with the
control plasmid, pSP6T7-EGFP-N1 (Fig. 8A, lane 3). However,
expression of GFP was not detected in cells transfected with the
pCMV-IR3 ORF/GFP plasmid (Fig. 8A, lane 1). Interestingly, a
protein of ∼29 kDa was detected in cells transfected with the
pCMV-GFP/IR3 ORF plasmid (Fig. 8A, lane 2), but a GFP-IR3
fusion protein of the expected size of ∼37 kDa (279+95=374
amino acids) was not detected. These findings suggest that the
IR3 transcript is not translated in vivo, and led us to examine
the possibility that sequences within the IR3 5′UTR may retard
translation. We cloned the IR3 5′UTR sequences into the control
pSP6T7-EGFP-N1 plasmid multiple cloning site that is 47 nt
downstream from the CMV-IE promoter Tci, and transfected this
plasmid into NBL-6 equine cells. As shown in Fig. 7D, GFP was
barely detectable in cells transfected with the pCMV-IR3 5′
UTR/GFP plasmid, suggesting that the IR3 5′UTR sequence
may harbor a negative element(s) for gene expression.
Next, the in vitro expression of the IR3 ORF, GFP, IR3 ORF/
GFP, and GFP/IR3 ORF genes was analyzed using IVTT. All
four proteins generated from pSP6T7-EGF-N1 (Fig. 4D, lane 3;
Fig. 8B, lane 2), pSV-IR3 ORF (Fig. 4D, lane 2), pCMV-IR3
ORF/GFP (Fig. 8B, lane 3), and pCMV-GFP/IR3 ORF (Fig. 8B,
lane 4) were detected at the predicted molecular weights. All
together, these findings suggest that IR3 RNA is translated to an
IR3 gene product in vitro by the use of an IVTT assay, but
translation of the IR3 transcript is greatly retarded under in vivo
conditions, possibly by both IR3 5′UTR and ORF sequences.
Discussion
In addition to the six regulatory genes that govern the EHV-1
gene program, our previous studies suggested that the EHV-1
Fig. 5. Detection of IR3 protein by immunological methods. (A) Detection of GST/IR3 fusion protein by western blot. GST/IR3 fusion protein and EHV-1 infected cell
extracts were prepared as described in Materials and methods. GST/IR3 fusion protein was detected using anti-IR3 antibody, and the UL5 protein was detected using
anti-UL5 antibody from EHV-1 infected cell extracts by western blot. Arrows in lanes 3 and 4 indicate the UL5 protein and the GST/IR3 fusion protein, respectively.
(B) Detection of the IR3 protein in extracts of EHV-1 infected radiolabeled cells. Preparation of radiolabeled IR3 and UL5 IVTT proteins and radiolabeling of EHV-1
infected cells were performed as described in Materials and methods. Radiolabeled IVTTs and radiolabeled cell extracts were reacted with anti-IR3 and anti-UL5
antibodies to probe for the presence of the IR3 and UL5 proteins in EHV-1 infected RK13 cells. The arrow in lane 3 indicates IVTT-synthesized IR3 protein; the arrow
in lane 9 indicates the UL5 protein from EHV-1 infected cell extract.
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within both the internal and terminal repeats of the short
genomic region as one of six diploid genes, and consists of a 5′Fig. 6. Assay for the IR3 protein in EHV-1 infected cells, cells transfected with
pSV-IR3, and cells cotransfected with pSVIE and pSV-IR3. Western blot
procedures were performed by using anti-IR3 antibody and anti-IE antibody as
described in Materials and methods. The same amount of each sample was
loaded on A and B. (A) Detection of the IEP using anti-IEP antiserum. The
∼200 kDa IEP was detected in EHV-1 infected cells and in cells transfected with
pSVIE and cells cotransfected with pSVIE and pSV-IR3 plasmids. As a loading
control (black bands at bottom), glyceraldehyde phosphate dehydrogenase
(GAPDH) was detected in cell lysates by using mouse anti-GAPDHmonoclonal
antibody (Chemicon international, Temecula, CA). Arrow indicates the
∼200 kDa IEP. (B) Assay for the IR3 protein using anti-IR3 antiserum. The
∼10 kDa IR3 protein was not detected in EHV-1 infected cells, or in cells
transfected with pSV-IR3, or cells cotransfected with pSVIE and pSV-IR3
plasmids. The rectangle indicates the expected location of the ∼10 kDa IR3
protein.UTR of 443 bases and an ORF of 285 bases. The IR3 lies
opposite to the IE gene, and the 5′ end of the IR3 transcript
harbors 117 nt that are antisense to the 5′UTR of the IE mRNA.
Here, these studies characterized the IR3 gene and revealed that
its functional promoter is trans-activated by EHV-1 regulatory
proteins. The finding that the IR3(+43/+443)-Luc exhibited
promoter activity above basal levels was unexpected, since the
IR3(+43/+443) region lacks the IR3 TATA box and Tci site,
and the IE TATA box sequences are located within the IR3(+43/
+443) sequences. These data suggest that the IR3(+43/+443)-
Luc may use the IE TATA box, and that a Tci site may lie within
the IR3(+43/+443) sequence. That the IR3(+43/+443) region
showed promoter activity may explain why a ∼600 nt IR3
transcript band was detected in northern blots using IR3 ORF
sequences as a probe.
The present studies also showed that the IEP is a potent
trans-activator of IR3 gene expression, which was not
surprising as DNA sequencing revealed that the IR3 promoter
harbors several target sequences for IEP binding. That these IEP
binding sites are functional was confirmed by gel shift assays
using DNA probes representative of the IR3 promoter region
and supershift assays using anti-IEP monoclonal antibody. The
IEP trans-activation of the IR3 promoter was synergized by
either the EHV-1 EICP0P or IR4 early regulatory protein. The
synergistic effect mediated by IR4 was not surprising as IR4
enhancement of IEP binding and trans-activation is well
documented for many EHV-1 promoters. However, the synergy
provided by the EICP0P on the late IR3 promoter was an
unexpected result because previous studies (Bowles et al., 2000;
Kim et al., 2003) showed that these two proteins have an
antagonistic effect on the expression of some late promoters,
such as those of the IR5 and gK late genes.
Fig. 7. Expression ofGFP, IR3 5′UTR/GFP, and GFP/IR3 ORF and IR3 ORF/GFP fusion genes. Plasmid pSP6T7-EGFP-N1, pCMV-GFP/IR3 ORF, pCMV-IR3 ORF/
GFP, or pCMV-IR3 5′UTR/GFP was transfected into equine NBL-6 cells by using the nucleofactor kit as described in Materials and methods. The expression of GFP
was observed using fluorescent microscopy at 48 h.p.t. Pictures in the top panels indicate green fluorescence (GF), and images in the lower panels are fluorescence and
light merged images.
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detect an IR3 protein in EHV-1 infected or pSV-IR3 ORF
transfected cells by immunological assays proved unsuccessful,
even though independently generated anti-IR3 antibodies wereFig. 8. Detection of GFP, IR3 ORF/GFP, and GFP/IR3 ORF proteins by western
blot and IVTT. (A) Detection of GFP, IR3 ORF/GFP, and GFP/IR3 ORF
proteins by western blot. Plasmids pCMV-IR3 ORF/GFP (lane 1), pCMV-GFP/
IR3 ORF (lane 2), and positive control pSP6T7-EGFP-N1 (lane 3) were
transfected into NBL-6 cells using the nucleofactor kit. Proteins in cellular
extracts were resolved by 12% SDS-PAGE and subjected to western blot
analysis using anti-GFP monoclonal antibody (Sigma, St. Louis, MO) as
described in Materials and methods. The IR3 ORF/GFP fusion protein of
∼37 kDa was not detected (lane 1). A truncated form (lane 2) of the GFP/IR3
ORF fusion protein, which is smaller than the expected size of ∼36 kDa, was
observed. The GFP of the expected size of 27 kDa was detected (lane 3). These
three vectors are under the control of the CMV promoter and identical Kozak
sequences. (B) Detection of GFP, IR3 ORF/GFP, and GFP/IR3 ORF proteins by
IVTT. The 35S-labeled GFP, IR3 ORF/GFP and GFP/IR3 ORF proteins
generated by IVTT were separated by 12% SDS-PAGE, and assayed by
autoradiography as described in Materials and methods. The sizes of 14C-labeled
protein molecular markers (CFA626, Amersham Biosciences, Piscataway, NJ)
are shown in lane 1. Arrows indicate the locations of 35S-labeled GFP (lane 2),
IR3 ORF/GFP (lane 3), and GFP/IR3 ORF (lane 4) proteins.shown by immunoprecipitation and western blot analyses to
bind to an IR3 protein synthesized in vitro and from an E. coli
expression system. In addition, an alternate approach to show
that the IR3 ORF was expressed in vivo as a fusion protein
from IR3 ORF/GFP and GFP/IR3 ORF fusion genes
controlled by the CMV-IE promoter likewise demonstrated
very poor, if any, translation of the IR3 transcript. In contrast,
results of IVTT assays showed products of the expected sizes
of the IR3 ORF, GFP/IR3 ORF, and IR3 ORF/GFP proteins.
Together, these data indicated that an IR3 protein is produced
in vitro and in an E. coli expression system, but that in vivo
synthesis of an IR3 protein does not occur to any extent or
occurs below detectable levels, suggesting that post-transcrip-
tional interference of the IR3 RNA may retard synthesis of an
IR3 protein.
As noted in the Introduction, a 117 nt portion of the late IR3
transcript is antisense to the 5′ UTR of the sole IE transcript.
Preliminary studies reveal that expression of the IR3 RNA in
transient expression assays results in the down-regulation of IE
gene expression. Whether this down-regulation of the IE gene
occurs by an antisense mechanism and possibly plays a role in
EHV-1 gene regulation at late times in the infected cells are
topics of ongoing experiments.
Materials and methods
Cell culture
The rabbit RK13 and equine NBL-6 cells used for transient
transfection assays were maintained with Eagle's minimal
essential medium supplemented with 100 units of penicillin/ml,
100 μg of streptomycin/ml, nonessential amino acids, and 5%
(or 10%) fetal bovine serum.
Construction of plasmids
The IE promoter, IR3 promoter, IR3 ORF [equal to IR3
(+444/+728)], and IR3 5′UTR [equal to IR3(+1/+443)] regions
were PCR-amplified using Accuprime pfx polymerase (Invitro-
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including the entire IR of the EHV-1 genome), and primers
containing proper restriction enzyme sites at the 5′ ends. The
PCR products were digested with appropriate restriction
enzymes and cloned into proper vectors using standard cloning
methods (Sambrook et al., 1989). All clones were confirmed by
sequence analysis. Based on the published sequences of the IR3
gene (Holden et al., 1992) and IE gene (Grundy et al., 1989),
the PCR products of IE(−993/+627) promoter region (primers,
5′ tag tct cga gtg tct caa gcc acg cc 3′ and 5′ aat aga tct ggc gtg
cta gct ccg gc 3′), and IR3 promoter region [IR3(+43/+443)
(primers: 5′ tat aag atc tca acg gcc aat cac aat cga tag tgt ggg 3′
and 5′ tat agg tac cgg ctt cga ggt aag tat ccc ca 3′); IR3(−280/
+443) (primers, 5′ tat aag atc tca acg gcc aat cac aat cga tag tgt
ggg 3′ and 5′ taa tgg tac ctg cta gct ccg gct tcg g 3′); IR3(−946/
+443) (primers, 5′ tat aag atc tca acg gcc aat cac aat cga tag tgt
ggg 3′ and 5′ tat tgg tac ctt cgt cgc tgt cgc tgt cg 3′); IR3(−946/
+38) (primers, 5′ tat tgg tac ctt cgt cgc tgt cgc tgt cg 3′ and 5′ tat
aag atc tca acg gcc aat cac aat cga tag tgt ggg 3′); and IR3(−946/
−85) (primers, 5′ acg aga tct ttc cct ttt acc att cgg ctc cgc 3′ and
5′ tat tgg tac ctt cgt cgc tgt cgc tgt cg 3′)] were digested by KpnI
and BglII, and cloned into pGL3-Basic vector (Promega,
Madison, WI) to generate plasmids [pIE(−993/+627)-Luc,
pIR3(+43/+443)-Luc, pIR3(−280/+443)-Luc, pIR3(−946/
+443)-Luc, pIR3(−946/+38)-Luc, and pIR3(−946/−85)-Luc,
respectively] (Fig. 1A). The PCR product of IR3 ORF (primers,
5′ tag gaa ttc gcg acc atg ggc ggt ggg ctg gta gcg 3′ and 5′ agc
tct aga tca cga acc ccg ttg gcg cga cgc 3′) was digested by KpnI
and XbaI, and cloned into pSVSPORT1 plasmid (Gibco, BRL,
Gaithersburg, MD) to generate pSV-IR3 ORF. When cloning
the IR3 ORF, Kozak sequences were created to enhance
translation of the IR3 transcript (Kozak, 1987). The pEGFP-N1
vector (Clontech, Mountain View, CA) was modified for in
vitro transcription/translation (IVTT). The PCR product of SP6/
T7 promoter sequences (template, 5′ taa tac gac tca cta tag gct
agc att tag gtg aca cta ta 3′; primers, 5′ aat gct agc taa tac gac tca
cta tag g 3′ and 5′ ttt aga tct tat agt gtc acc taa atg c 3′) was
digested by NheI and BglII, and cloned into pEGFP-N1 vector
(it was named pSP6T7-EGFP-N1). To construct the IR3 5′
UTR/GFP fusion gene, the PCR product of the IR3 5′UTR (5′
att aga tct tcc gcc gag gca gaa gcc g 3′ and 5′ att ggt acc caa cgg
cca atc aca gat agt g 3′) was digested by BglII and KpnI, and
cloned into the multiple cloning site of pSP6T7-EGFP-N1
plasmid (it was named pCMV-IR3 5′UTR/GFP). For the IR3
ORF/GFP fusion gene construction, the PCR product of the IR3
ORF (primers, 5′ att ggt acc tgc gac cat ggg cgg tgg gcg tgt agc
g 3′ and 5′ ttt aga tct ttc gaa ccc cgt tgg cgc gac gc 3′) was
digested by KpnI and BglII, and cloned into pSP6T7-EGFP-N1
vector (it was named pCMV-IR3 ORF/GFP). The IR3 ORF/
GFP fusion gene was confirmed to be in-frame, and Kozak
sequences were created at the 5′ end of the IR3 ORF. To
construct the GFP/IR3 ORF fusion gene, the PCR product of
the IR3 ORF (primers, 5′ ata tgt aca aga tgg gcg gtg ggc gtg tag
cg 3′ and 5′ att gcg gcc gct cac gaa ccc cgt tgg cg 3′) was
digested by BsrGI and NotI, and cloned into pSP6T7-EGFP-N1
vector (it was named pCMV-GFP/IR3 ORF). The IR3 ORF was
fused in-frame to the 3′ end of the GFP (green fluorescentprotein) gene. To construct GST/IR3 fusion gene, PCR product
of IR3 ORF (primers, 5′ 5′ cgg aat tca gat atc cag gct tcc gcg 3′
and 5′ tta ggt cga ctc acg aac ccc gtt ggc gcg acg c 3′) was
digested with EcoRI and SalI, and cloned into pGEX-4T-1
vector and transformed into E. coli BL21 (Pharmacia, New
York, NY) (it was named pGST-IR3).
Expression and purification of GST/IR3 fusion gene
BL21 cells containing pGST-IR3 were cultured in LB
medium until the cells reached to an OD600 of 0.6 at 37 °C, and
incubated for an additional 2 h with 0.1 mM isopropyl
thiogalactoside (IPTG). Cells were harvested, and purification
of the GST/IR3 fusion protein was performed using the GST
Gene Fusion System (Pharmacia) according to the manufac-
turer's directions.
Luciferase assay
80% confluent RK13 cells were prepared in 24-well plates,
and 1 pmol of reporter plasmid and 0.5 pmol of effector
plasmids were used in transfection assays. Effector plasmids
(pSVIE, pSVEICP0, pSVEICP22, pSVEICP27, pSVETIF and
pSV-IR3 ORF) were used as previously described (Bowles et
al., 2000; Holden et al., 1992; Kim and O'Callaghan, 2001;
Smith et al., 1992; Zhao et al., 1995). Six microliters of
lipofectin (Invitrogen) was mixed with 330 μl of Opti-MEM
medium (Gibco, BRL) and incubated for 45 min at room
temperature. The effector and reporter plasmids were mixed
with 330 μl of Opti-MEMmedium, and total DNAwas adjusted
to the same amount with pSVSPORT1 DNA. The two mixtures
were combined and incubated at room temperature for 15 min,
and one-third of the volume was transferred into each of three
wells after RK13 cells were washed three times with Opti-
MEM. At 8 h post-transfection (h.p.t.), normal growth medium
was added, and at 48 h.p.t., luciferase activity (relative
luciferase unit: RLU; Alam and Cook, 1990) was measured
using a luciferase assay kit (Promega) and POLARstar
OPTIMA plate reader (BMG LABTECH Inc., Burham, NC)
according to the manufacturer's directions.
Gel shift assay
The PCR products of IR3(+43/+443) and IR3(−946/+38)
were end-labeled with [γ-32P]ATP (New England Nuclear
Corporation, Boston, MA) and T4 polynucleotide kinase
(Promega) according to the manufacturer's directions. The
DNA binding assay and purification of glutathione S-transfer-
ase-IE fusion protein (GST-IEP) were conducted as previously
described (Kim et al., 1995). The DNA binding reactions
contained approximately 1 ng of radiolabeled DNA fragments
(2×105 cpm/ng), 0.1 μg of poly(dI-dC) as a nonspecific
competitor, and 100 ng of indicated protein in 20 μl of binding
buffer (20 mM HEPES-KOH [pH 7.9], 0.5 mM dithiothreitol,
10% glycerol, 0.1 mM EDTA, 0.025% NP-40, 25 mM KCl,
2 mMMgCl2). The PCR product of SP6T7 promoter sequences
described above was used as a nonspecific competitor DNA.
As specific competitors, 300 ng of unlabeled PCR products of
IR3(+43/+443) and IR3(−946/+38) was used. To confirm the
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clonal antibody A1.4 to the IEP (Caughman et al., 1995) was
included in selected reactions. As a control serum, anti-GFP
mouse monoclonal antibody (Sigma, St. Louis, MO) was used.
The DNA binding reaction mixtures were incubated at room
temperature for 20 min. In the antibody-containing reactions,
specific and nonspecific antisera were added to the indicated
reactions after the initial 20 min incubation, and the reactions
were incubated for another 20 min at room temperature. After
reaction, 5 μl of loading buffer (200 mM HEPES-KOH [pH
7.9], 50% [vol/vol] glycerol, 0.02% bromphenol blue) was
added, and the reaction samples were separated by electro-
phoresis using a 3% polyacrylamide gel with 0.5× Tris–
borate–EDTA running buffer and 3% glycerol [vol/vol] for 3 h
at 200 V followed by autoradiography using a phosphorimage
screen and molecular imager FX system (Bio-Rad Labora-
tories, Hercules, CA).
Preparation of anti-IR3 antisera
A 20-amino acid peptide (20-mer; MHISSACVSSPG-
SASRQRGS) corresponding to residues 76 to 95 of the
predicted 95-amino acid IR3 protein and a 13-amino acid
peptide (13-mer; CIKVNAPGRHDTS) corresponding to resi-
dues 63 to 75 were synthesized and coupled via the C residue to
keyhole limpet hemocyanin (United States Biochemicals,
Cleveland OH) by using glutaraldehyde or m-maleimido-
benzoyl-N-hydroxysuccinimide ester (Harlow and Lane,
1988). For the primary immunization, New Zealand White
rabbits were injected intramuscularly with 0.5 mg of peptide-
carrier conjugate emulsified in complete Freund's adjuvant (1:1,
vol:vol; Sigma). For subsequent immunizations, administered at
2 to 4 week intervals, 0.25 mg of peptide-carrier conjugate
emulsified in incomplete Freund's adjuvant (Sigma) was used.
Peptide-specific antibodies were readily detected by their
reaction with the peptide in a dot blot assay (Harlow and
Lane, 1988) and subsequently by their reaction with IR3 protein
synthesized by in vitro coupled transcription and translation
(IVTT) (see below).
DNA transfection by nucleofector
DNA transfection was performed using a nucleofactor kit
(Amaxa Inc., Gaithersburg, MD) according to the manufac-
turer's directions. Equine NBL-6 cells (2×106 cells/each
transfection) were mixed with 100 μl of Nucleofector solution
and 2 pmol of plasmid DNA (total DNA was adjusted to 5 μg
with pSVSPORT1). The mixture was electrophorated using
Program T-30. After transfection, cells were resuspended in E-
MEM with 10% FBS and transferred into a 60-mm culture dish.
After 24 h.p.t., the cells were examined, harvested, and
analyzed. Cells transfected with plasmids that express GFP,
GFP/IR3 ORF, IR3 5′UTR/GFP, or IR3 ORF/GFP were
examined using fluorescent microscopy to assess expression
of the GFP, and cell extracts from plasmid transfected cells
were then used in western blot assays to detect the expressed
protein.Extraction of protein and total RNA from EHV-1 infected RK13
cells
90% confluent RK13 cells in T75 flask were infected with
EHV-1 KyA at an m.o.i. of 10 at 4 °C with gentle rocking to
synchronize the infection. After 2 h, the cells were washed twice
with warm medium, and incubated at 37 °C for 1 to 7 h. Cells
were harvested in PBS, collected by low speed centrifugation,
and used for total RNA extraction [at 0, 1, 3, 5, and 7 h post
infection (h.p.i.)] and protein extraction (at 7 h.p.i). Extraction
of whole-cell lysates was performed as previously described
(Kim et al., 2006) and total RNA was extracted from virus
infected RK13 cells by using the RNA-Bee RNA isolation kit
(Tel-Test, Inc., Friendwood, TX). The virus infected whole-
cell lysates and RNA extracts were stored at −80 °C until
use.
Western blot and northern blot analyses
For protein detection, the whole-cell lysates from virus
infected and DNA transfected cells and IR3 protein from IVTT
were separated by dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE), and then transferred to a nitrocellulose
membrane (Ambion, Austin, TX) by using a semi-dry
electroblotter (Bio-Rad Laboratories). The GFP, GFP/IR3
ORF, and IR3 ORF/GFP proteins were detected using anti-
GFP mouse monoclonal antibody (Sigma) and a western blot
detection kit (Amersham Biosciences, Piscataway, NJ) accord-
ing to the manufacturer's directions. For the detection of other
viral proteins, anti-IEP polyclonal antibody (Caughman et al.,
1995) for IEP, anti-IR3 antiserum for IR3 protein, or anti-UL5
antiserum (Albrecht et al., 2003) for UL5 was used as primary
antibody, and anti-rabbit IgG[Fc]-alkaline phosphatase con-
jugate (Promega) was used as secondary antibody. Proteins
were visualized by incubating the membrane containing blotted
protein in AP conjugate substrate (AP conjugate substrate kit,
Bio-Rad Laboratories) according to the manufacturer's direc-
tions. For the detection of the IR3 transcript, the DNA probe
(IR3 ORF PCR product) was radiolabeled as before. RNA
samples from virus infected RK13 cells were separated by
electrophoresis in 3% denaturing acrylamide gel (8 M Urea) and
transferred to a nylon membrane (Ambion) by using a semi-dry
electroblotter (Bio-Rad Laboratories). Prehybridization, hybri-
dization, and washing were performed using the NorthernMax
Kit (Ambion) followed by autoradiography using a phosphor-
image screen and the molecular imager FX system (Bio-Rad
Laboratories).
In vitro coupled transcription and translation (IVTT) reactions,
metabolic labeling of EHV-1 infected cells, and
immunoprecipitation of radiolabeled proteins
The IVTTs were performed with the TnT quick-coupled
rabbit reticulocyte lysate system (Promega) and 3.0 μl of
1175Ci/mmol EasyTag Express Protein Labeling Mix (Perkin-
Elmer, Wellesley, MA) containing 35S-cys/met according to the
manufacturer's directions. For IVTT reactions, pSVUL5,
pCMV-IR3 ORF/GFP, pCMV-GFP/IR3 ORF, pSP6T7-EGF-
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of EHV-1 infected RK13 cells was performed as follows: Six
60 mm dishes of confluent RK13 cells were mock infected or
infected with EHV-1 at a MOI of 10. At 7 h.p.i, the cells were
washed twice with PBS and incubated in 1× DMEM (Media-
tech, Herndon VA) supplemented with glutamine, and deficient
in methionine and cysteine for 30 min. The cells were then
incubated with 2 ml of 1× DMEM containing 0.24 mCi/ml of
[35]-S labeled cys/met (New England Nuclear) for a period of 4
h to allow for recovery of translation and incorporation of the
radiolabeled amino acids into late viral proteins. The mono-
layer was harvested in PBS and pelleted, and whole-cell
extracts were prepared as described previously. Antibodies
raised against IR3 and UL5, and preimmune serum were
adsorbed to S. aureus protein-A conjugated beads (Sigma),
then 50 μl of mock infected, infected whole-cell extracts, or
IVTT products was added, and the total volume for each
sample was adjusted to 500 μl with co-IP buffer [50 mM Tris–
Cl, pH 7.5, 15 mM EGTA, 100 mM NaCl, 0.1%(w/v) Triton X-
100, proteinase inhibitor cocktail (Sigma), 1 mM DTT]. The
mixture was incubated for 2 h at 4 °C, washed three times with
1 ml of co-IP buffer, pelleted, resuspended in protein loading
buffer (BioRad), and boiled for 5 min. The precipitated
products were assayed by 12% SDS-PAGE analysis and
autoradiography.
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